Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 13;16(8):e66792.
doi: 10.7759/cureus.66792. eCollection 2024 Aug.

The Revolution of Digital Therapeutics (DTx) in the Pharmaceutical Industry and Their Quality Impacts

Affiliations
Review

The Revolution of Digital Therapeutics (DTx) in the Pharmaceutical Industry and Their Quality Impacts

Anuciya Rajendran et al. Cureus. .

Abstract

An increasing number of developments and trends are driving the expansion of the digital therapeutics (DTx) market in the pharmaceutical industry. Digital therapeutics are therapies intended to treat, diagnose, and prevent diseases by using patient-directed clinically assessed software applications, which can optimize the effectiveness and delivery of healthcare. These digital innovations became important as the world changed, particularly during the coronavirus pandemic. Nowadays pharma companies are getting more comfortable with the idea of digital therapies. The majority of pharmaceutical companies are examining how to incorporate pharmaceuticals and digital therapies into their treatment regimens, leveraging digital tools to enhance patient outcomes and streamline healthcare delivery. A thorough overview of the most recent technological advancements in the creation of digital therapies shows particular technologies that are essential to the market's future growth. Moreover, the evaluation of digital therapeutics by clinical trial and real-world data is outlined. The critical quality attributes of DTx products and the challenges, including data management issues and regulatory obstacles, which make the creation, approval, and marketing of customized medicines more difficult, are covered in this review article. Overall, pharma companies are venturing into the world of digital therapeutics while acknowledging the limitations of the emerging field.

Keywords: digital health technologies (dht); digital technologies; digital therapeutics (dtx); medical device; software systems.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Traditional processing method and digital processing method
Analysis of Biomedical Images: Artificial intelligence (AI) has the potential to streamline the diagnostic process for image specialists and yield faster health outcomes by eliminating the need for several steps in the review and diagnosis process, which is a common practice in traditional approaches. AI can assist with detecting illnesses that are sometimes hard for the human eye to perceive and diagnose, as well as identifying, classifying, and extracting pathological regions more quickly and with precision in diagnosis. From Ona, S. (2023). "Revolutionizing Our Healthcare: Harnessing AI's Potential for Health and Medicine". https://app.biorender.com/biorender-templates/t-65270cd349c5b1089b610edd-revolutionizing-our-healthcare-harnessing-ais-potential-for-

Similar articles

Cited by

References

    1. Introduction of digital therapeutics. Hong JS, Wasden C, Han DH. Comput Methods Programs Biomed. 2021;209:106319. - PubMed
    1. Going digital - a commentary on the terminology used at the intersection of physical activity and digital health. Herold F, Theobald P, Gronwald T, Rapp MA, Müller NG. Eur Rev Aging Phys Act. 2022;19:17. - PMC - PubMed
    1. Digital therapeutics: an updated review. Akhtar N, Sami H, Jain A, Singhai AK. https://www.researchgate.net/publication/374558662 Inventi Rapid: NDDS. 2023;2023:1–5.
    1. Digital therapeutics for improving effectiveness of pharmaceutical drugs and biological products: preclinical and clinical studies supporting development of drug + digital combination therapies for chronic diseases. Biskupiak Z, Ha VV, Rohaj A, Bulaj G. J Clin Med. 2024;13:403. - PMC - PubMed
    1. Cutting-edge technologies for digital therapeutics: a review and architecture proposals for future directions. Yoo JH, Jeong H, Chung TM. Appl Sci. 2023;13:6929.

LinkOut - more resources